Press Releases

02-07-2023	Pliant Therapeutics to Participate in Upcoming Investor Events
02-02-2023	Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
01-27-2023	Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
01-25-2023	Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
01-24-2023	Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
01-23-2023	Pliant Therapeutics Announces Proposed Public Offering of Common Stock
01-22-2023	Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
01-03-2023	Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference